Table 4 Mapping of main categories and core categories into the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) headings
OMERACT heading | Life impact | Pathophysiology | Resource use/economic impact | Adverse events | Death | ||||
|---|---|---|---|---|---|---|---|---|---|
1 | Patient subjective perception of health and severity of symptoms | Number of trials to use the outcome | Physiological assessments | Number of trials to use the outcome | Cost | Number of trials to use the outcome | Medical | Number of trials to use the outcome | Not reported by any clinical trials |
a. Global | 13 | a. Endoscopic | 55 | a. Personal | 0 | 32 | |||
b. Disease-specific | 51 (measured primarily with the Visual Analogue Score (VAS) | b. Radiological | 25 | b. Societal | 0 | ||||
c. Individual Lower airways | 4 | c. Nasal airflow | 26 | ||||||
d. Mucociliary function | 7 | ||||||||
e. Olfactory testing | 10 | ||||||||
f. Sinus manometry | 11 | ||||||||
g. Respiratory function test | 5 | ||||||||
2 | Quality of life | Microbiological | 11 | Need for rescue medications | 10 | Surgical | 1 | ||
a. Global | 10 (most common outcome measure used was the SF-36) | ||||||||
b. Disease-specific | 13 (SNOT, RSDI, RSOM 31) | ||||||||
3 | Resource utilisation | Biomarkers | 15 | Need for revision surgery | 1 | ||||
a. Compliance | 7 | ||||||||
b. Acceptability | 2 | ||||||||
c. Patient preference | 1 |